Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Tolerability of UCB0107 in Progressive Supranuclear Palsy
NCT04658199Phase 1Active, not recruiting
- Sponsor
- UCB
- Start
- Nov 2020
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of Bepranemab in progressive supranuclear palsy (PSP), sponsored by UCB. Primary endpoint: Incidence of treatment emergent adverse events up to 7 years. Started Nov 2020; status: active, not recruiting.
02
Drugs
Bepranemab
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT04658199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658199.